BioSpace News Archive

Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor antagonists to treat and prevent hereditary angioedema (HAE) attacks, today reported financial results for the third quarter ended September 30, 2022, and provided a business update.

Spago Nanomedical today announced that the first patient in the Phase IIa clinical study with SpagoPix in endometriosis, SPAGOPIX-02, has been successfully dosed with the contrast agent SN132D and undergone magnetic resonance imaging (MRI).

Microbot Medical Inc. (Nasdaq: MBOT) continues to strengthen its intellectual property (IP) portfolio, while advancing and securing its global commercialization strategy.

Trevena, Inc. today announced that three abstracts related to the Company’s commercial and clinical pipeline were presented at medical meetings in December.

Instil Bio, Inc. today announced a reprioritization of its clinical programs to focus on development of its CoStAR-TIL product candidates.

Baudax Bio, Inc. today announced the initiation of a clinical study evaluating the safety, tolerability profile, and intubation conditions of BX1000 for neuromuscular blockade (NMB) in patients undergoing elective surgery.

Alimera Sciences, Inc. today announced that it has agreed to an amendment to its existing loan and security agreement with its debt facility partner, SLR Investment Corp (“SLR”) to extend the interest-only period through March 31, 2023.

Dragonfly also announced this week its first TriNKET, HER2-targeting DF1001, entered Phase 2.

Promontory Therapeutics Inc. today presented Phase 2a clinical safety and efficacy data on lead therapeutic candidate PT-112 in combination with PD-L1 inhibition, in patients with advanced non-small cell lung cancer (NSCLC) at the European Society for Medical Oncology Immuno-Oncology (ESMO I-O) Congress 2022.

Exelixis, Inc. (Nasdaq: EXEL) today announced initial results from the ongoing dose-escalation stage of QUARTZ-101, a phase 1 clinical trial evaluating XL102, a potent, selective, irreversible and orally bioavailable small molecule cyclin-dependent kinase 7 (CDK7) inhibitor, in patients with advanced solid tumors.